Life sciences business Aptamer said on Monday that its current sales pipeline was "strong", with over £3.0m in advanced stage ...

Using a molecule known as an aptamer, which has already revolutionized cancer diagnostics recently, the team have ...

Most importantly, Dr. Lee has applied the newly developed technology to capture structural transformation in four states of ...

Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, today announces the progression of a partnership with Kairos Biotech, an early-stage ...

Aptamer-based theranostics have gained attention in the field of cancer research and treatment. Aptamers can be used as targeting ligands for the delivery of therapeutic agents to cancer cells ...

GUELPH, ON / ACCESSWIRE / /Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned ...

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently ...

The potential of utilizing RNA helixes in a molecular lever system could be harnessed to develop innovative antibacterial ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Aptamer said its current sales pipeline is strong, with over GBP3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the ...

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the progression of a partnership with Kairos Biotech ...